Alendronate
"Alendronate" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A nonhormonal medication for the treatment of postmenopausal osteoporosis in women. This drug builds healthy bone, restoring some of the bone loss as a result of osteoporosis.
Descriptor ID |
D019386
|
MeSH Number(s) |
D02.705.429.500.100
|
Concept/Terms |
Alendronate- Alendronate
- Aminohydroxybutane Bisphosphonate
- Bisphosphonate, Aminohydroxybutane
- 4-Amino-1-Hydroxybutylidene 1,1-Biphosphonate
- 4 Amino 1 Hydroxybutylidene 1,1 Biphosphonate
Alendronate Sodium- Alendronate Sodium
- Sodium, Alendronate
- Alendronate Monosodium Salt, Trihydrate
|
Below are MeSH descriptors whose meaning is more general than "Alendronate".
Below are MeSH descriptors whose meaning is more specific than "Alendronate".
This graph shows the total number of publications written about "Alendronate" by people in this website by year, and whether "Alendronate" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
Year | Major Topic | Minor Topic | Total |
---|
2001 | 1 | 0 | 1 | 2003 | 1 | 0 | 1 | 2004 | 1 | 0 | 1 | 2017 | 0 | 1 | 1 | 2019 | 2 | 0 | 2 |
To return to the timeline, click here.
Below are the most recent publications written about "Alendronate" by people in Profiles.
-
Cardet JC, Jiang X, Lu Q, Gerard N, McIntire K, Boushey HA, Castro M, Chinchilli VM, Codispoti CD, Dyer AM, Holguin F, Kraft M, Lazarus S, Lemanske RF, Lugogo N, Mauger D, Moore WC, Moy J, Ortega VE, Peters SP, Smith LJ, Solway J, Sorkness CA, Sumino K, Wechsler ME, Wenzel S, Israel E. Reply. J Allergy Clin Immunol. 2019 09; 144(3):873-874.
-
Cardet JC, Jiang X, Lu Q, Gerard N, McIntire K, Boushey HA, Castro M, Chinchilli VM, Codispoti CD, Dyer AM, Holguin F, Kraft M, Lazarus S, Lemanske RF, Lugogo N, Mauger D, Moore WC, Moy J, Ortega VE, Peters SP, Smith LJ, Solway J, Sorkness CA, Sumino K, Wechsler ME, Wenzel S, Israel E. Loss of bronchoprotection with ICS plus LABA treatment, ß-receptor dynamics, and the effect of alendronate. J Allergy Clin Immunol. 2019 08; 144(2):416-425.e7.
-
Adebayo OO, Ko FC, Wan PT, Goldring SR, Goldring MB, Wright TM, van der Meulen MCH. Role of subchondral bone properties and changes in development of load-induced osteoarthritis in mice. Osteoarthritis Cartilage. 2017 12; 25(12):2108-2118.
-
Day JS, Ding M, Bednarz P, van der Linden JC, Mashiba T, Hirano T, Johnston CC, Burr DB, Hvid I, Sumner DR, Weinans H. Bisphosphonate treatment affects trabecular bone apparent modulus through micro-architecture rather than matrix properties. J Orthop Res. 2004 May; 22(3):465-71.
-
Ding M, Day JS, Burr DB, Mashiba T, Hirano T, Weinans H, Sumner DR, Hvid I. Canine cancellous bone microarchitecture after one year of high-dose bisphosphonates. Calcif Tissue Int. 2003 Jun; 72(6):737-44.
-
Adachi JD, Saag KG, Delmas PD, Liberman UA, Emkey RD, Seeman E, Lane NE, Kaufman JM, Poubelle PE, Hawkins F, Correa-Rotter R, Menkes CJ, Rodriguez-Portales JA, Schnitzer TJ, Block JA, Wing J, McIlwain HH, Westhovens R, Brown J, Melo-Gomes JA, Gruber BL, Yanover MJ, Leite MO, Siminoski KG, Nevitt MC, Sharp JT, Malice MP, Dumortier T, Czachur M, Carofano W, Daifotis A. Two-year effects of alendronate on bone mineral density and vertebral fracture in patients receiving glucocorticoids: a randomized, double-blind, placebo-controlled extension trial. Arthritis Rheum. 2001 Jan; 44(1):202-11.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|